3.8 Article

In-vitro analysis of the contribution of CYP2D6.35 to ultrarapid metabolism

Journal

PHARMACOGENETICS
Volume 11, Issue 8, Pages 739-741

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00008571-200111000-00014

Keywords

catalytic activity; CYP2D6.35; debrisoquine; ultra-rapid metabolism

Ask authors/readers for more resources

From 10 to 30% of CYP2D6 ultra-rapid metabolizers of Caucasian origin harbor alleles with duplicated or amplified functional CYP2D6 genes. Recently, the CYP2D6*35 allele has been reported to be more frequent in ultra-rapid metabolizing subjects than in extensive metabolizers, suggesting a possible role of this variant in CYP2D6 duplication-negative ultra-rapid metabolizing subjects. In this study, we examined the functional consequences of the Val(11)Met, Arg(296)Cys and Ser(486)Thr amino acid substitutions associated with the CYP2D6*35 on the expression and catalytic activity of the variant enzyme, heterologously expressed in yeast. Our results indicate that the functional activity and level of expression of recombinant CYP2D6.35 are comparable with those of the wild-type enzyme, thus precluding the hypothesis that the high level of enzyme activity in CYP2D6 duplication-negative ultra-rapid metabolizing subjects is a consequence of the expression of a more catalytically effective CYP2D6.35 enzyme. Pharmacogenetics 11:739-741 (C) 2001 Lippincott Williams & Wilkins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available